Argent BioPharma Issues 2.5 Million New Shares Under Regulatory Exemption

Argent Biopharma ( (AU:RGT) ) just unveiled an update.

Argent BioPharma has announced the issuance of 2,500,000 fully paid ordinary shares, which are exempt from the on-sale restrictions under the Corporations Act 2001. This strategic move aligns with the company’s compliance with the Act’s provisions and supports its ongoing efforts to enhance its financial position and operational capabilities in the biopharmaceutical industry.

More about Argent Biopharma

Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company that focuses on neuroimmunology and advanced nanomedicine. The company leverages its Neuro-Immune Modulatory (NIM) System to develop a pipeline of products, including CannEpil®, CogniCann®, and CimetrA®, targeting central nervous system disorders and immune-related conditions. Argent BioPharma is committed to advancing cannabinoid-based therapeutics and neuroimmune modulation.

YTD Price Performance: -20.83%

Average Trading Volume: 554

Technical Sentiment Signal: Buy

Current Market Cap: $6.82M

For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.